WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Bioverativ
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
Biogen | December 22, 2016
Biogen Inc. (NASDAQ: BIIB) today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the Registration Statement on Form 10 filed by Bioverativ Inc. Biogen expects to complete the separation of Bioverativ into an independent, global biotechnology company focused on hemophilia and other rare blood disorders on February 1, 2017....
Biogen | December 21, 2016
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen’s hemophilia business, will present as well. That webcast will be live on Thursday, January 5, 2017 at 3:15p.m. ET. To access the live webcasts, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of ...
Biogen | November 15, 2016
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen’s hemophilia business, will present as well. That webcast will be live on Thursday, January 5, 2017 at 3:15p.m. ET. The planned spin-off of Bioverativ is expected to be completed on February 1, 2017....
fiercebiotech | September 06, 2017
Biogen’s newly spun off hemophilia biotech Bioverativ has signed a new pact with U.K. biotech Bicycle Therapeutics. The pair will ride tandem on new research work for hemophilia and sickle cell disease with the help of the biotech’s bicyclic peptide platform (the eponymous Bicycle). Bicycles combine attributes of antibodies, small molecules and peptides within one molecule, which the company says should allow “high selectivity and affinity” while at the same time being ab...
INDUSTRIAL IMPACT
Whitepaper
MEDICAL
Video
MEDTECH
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE